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Abstract Anti-estrogen and anti-HER2 treatments have
been among the first and most successful examples of
targeted therapy for breast cancer (BC). However, the
treatment of triple-negative BC (TNBC) that lack estrogen
receptor expression or HER2 amplification remains a major
challenge. We previously discovered that approximately
two-thirds of TNBCs express vitamin D receptor (VDR)
and/or androgen receptor (AR) and hypothesized that
TNBCs co-expressing AR and VDR (HR2-av TNBC)
could be treated by targeting both of these hormone
receptors. To evaluate the feasibility of VDR/AR-targeted
therapy in TNBC, we characterized 15 different BC lines
and identified 2 HR2-av TNBC lines and examined the
changes in their phenotype, viability, and proliferation after
VDR and AR-targeted treatment. Treatment of BC cell
lines with VDR or AR agonists inhibited cell viability in a
receptor-dependent manner, and their combination
appeared to inhibit cell viability additively. Moreover, cell
viability was further decreased when AR/VDR agonist
hormones were combined with chemotherapeutic drugs.
The mechanisms of inhibition by AR/VDR agonist hor-
mones included cell cycle arrest and apoptosis in TNBC
cell lines. In addition, AR/VDR agonist hormones induced
differentiation and inhibited cancer stem cells (CSCs)
measured by reduction in tumorsphere formation effi-
ciency, high aldehyde dehydrogenase activity, and CSC
markers. Surprisingly, we found that AR antagonists
inhibited proliferation of most BC cell lines in an AR-
independent manner, raising questions regarding their
mechanism of action. In summary, AR/VDR-targeted
agonist hormone therapy can inhibit HR2-av TNBC
through multiple mechanisms in a receptor-dependent
manner and can be combined with chemotherapy.
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Introduction
Breast cancers (BCs) are categorized in the clinic into three
subtypes, including, estrogen receptor positive (ER?),
epidermal growth factor receptor 2 positive (HER2?), and
triple-negative BCs (TNBCs) [1]. Treatment of ER? and
HER2? BCs has been successful through targeted therapy
with anti-estrogen and anti-HER2 drugs. Due to the lack of
these targets, neo-adjuvant chemotherapy is used for
treatment of TNBC that are typically associated with
poorer prognosis compared to other BC subtypes [2, 3]. In
addition, up to half of the ER? tumors eventually become
resistant to anti-estrogens [4–6]. Therefore, there is an
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urgent need to identify and develop novel targeted therapy
approaches for TNBC and hormone refractory ER? BCs.
In an attempt to develop a normal cell lineage-based
phylogenetic BC classification [7], we previously studied
hormone receptors (HRs) in normal human breast tissues
and compared them with human BCs [1]. To do so, we
used multiplex immunofluorescent staining and analyzed
simultaneous co-expression of the 14 lineage markers in
*15,000 normal breast cells and *3000 BCs, and found
that both normal luminal breast cells and BCs conform to
four hormonal states (HR3, HR2, HR1, and HR0) based on
co-expression of ER, androgen receptor (AR) and vitamin-
D (Vit-D) receptor (VDR) [1]. We also found that there
was 6.9-fold difference in overall survival between HR3
versus HR0 tumors [1]. Compared to the 1.7–2.1-fold
differences typically reported in overall survival between
ER?/LumA versus TNBC/basal-like BC [8, 9], these
results suggest that the HR0–3 classification reveals BC
sub-groups with highly significant outcome differences.
Utilizing the HR0–3 classification, we discovered that
approximately two-thirds of TNBCs co-express AR and
VDR (HR2-av TNBC) or express VDR alone (HR1-v
TNBC); the remaining one-third of the TNBCs are triple
negative for ER, AR, and VDR (HR0 TNBC) [1]. These
findings raised the possibility of developing novel HR-
targeted therapies for TNBC, for which the only existing
option is chemotherapy at the moment. In the present
study, we demonstrate that HR1-v and HR2-av TNBC cell
lines can be targeted with AR and/or VDR agonist hor-
mones alone and in combination. The combined effects of
AR and VDR ligands not only reduce the viability of the
cells, but also change their cancer stem cell (CSC) phe-
notype and differentiation. In addition, we found that AR
and VDR agonist hormones can be combined with
chemotherapeutic agents to successfully target TNBC cells.
Materials and methods
Cell culture and drug viability
All the BC and prostate cancer (PC) cell lines were pur-
chased from ATCC and DSMZ and cultured in their
respective media. The short tandem repeat profiling was
used to validate the authenticity of the cell lines (Genetic
Resources Core Facility, John Hopkins School of Medi-
cine). All the drugs were prepared and used according to
concentrations that were previously reported [10–14],
detailed information for each drug is provided in Supple-
mental Table 2. Cell viability assays were carried out in 24
or 96 well plates with cell titer cell reagent as previously
described [15]. The LD50 values of all the AR antagonists
were calculated as described previously [16]. See
supplemental methods for further details and analysis of
additive or antagonistic activity determined by Bliss
independent criterion.
Cell cycle and apoptosis assays
The cell cycle profile after AR or VDR agonist treatment
was evaluated by bromodeoxy uridine (BrdU) pulse
labeling followed by FACS analysis. Apoptosis was mea-
sured with FACS analysis of Annexin V and propidium
iodide double staining following the manufacture’s proto-
col (Life Technologies). See supplemental methods for
further details.
Tumorsphere and AldeFluor assays
Tumorsphere assays were performed as described previ-
ously [15]. AldeFluor assays were performed as described
[17] using ALDEFLUOR kit (StemCell Technologies).
The cells were treated with agonist(s) for 8 days with
media changes every 3 days and analyzed according to
manufacturer’s protocol by FACS. See supplemental
methods for further details.
PCR-based human stem cell array
Human stem cell RT2 ProfilerTM PCR array was used and
data were analyzed according to manufacturer’s protocol
and software (SA Biosciences). The genes with a 2-fold
difference compared to the vehicle treated control group
were shortlisted and plotted as a Heatmap generated using
Microsoft Excel.
Statistical analysis
The statistical significance of the data was evaluating by
performing Student’s T test using a cut-off of P-value
\0.05.
Results
Majority of TNBC cell lines express AR and/or VDR
In order to identify BC cell lines that represent HR1-v,
HR2-av, and HR0 phenotypes, we selected 15 lines based
on their previously published profiles. Two well-estab-
lished AR? (LNCaP and LAPC-4) and two AR- (PC-3
and DU-145) PC cell lines were used to provide bench-
mark for relative scale of AR expression. Among the 15
BC cell lines, seven were TNBC (Fig. 1a) that included
HR0 (BT-549 and SUM-1315), HR1-v (BT-20, MDA-MB-
468 and SUM-159PT), and HR2-av (MFM-223 and CAL-
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148) cell lines (Fig. 1d). In addition to confirming these
phenotypes with western blots, we tested the response of
these cell lines to physiologic levels of AR and VDR
agonists and determined that the cells we designate as
HR1-v respond to VDR agonists but not AR agonists,
HR2-av cell lines respond to both AR and VDR agonists,
and HR0 cells did not respond to either AR or VDR
agonists (Fig. 1b, c; Suppl. Fig. 1b). Therefore, the phe-
notypic HR0, HR1-v, and HR2-av designation of the cells
in Fig. 1b are based on both biochemical AR and VDR
expression and response to physiologic concentrations of
their natural ligands.
Inhibition of TNBC cell lines with calcitriol is VDR
dependent
The role of VDR has been studied in cancers, showing that
ligand bound VDR induces anti-proliferative, pro-apop-
totic, and pro-differentiating effects both in vitro and
in vivo [13, 18]. Here, we confirmed that natural VDR
agonist 1a,25-dihyroxy vitamin D3 (calcitriol) inhibits cell
viability in BC cell lines (Fig. 1b). No inhibition of cell
viability was observed in VDR- breast cell line BT-549
demonstrating that the response to calcitriol is VDR
dependent.
Fig. 1 Evaluation of androgen and vitamin D receptor agonists
response in BC lines: a Western blot analysis of 15 breast cancer cell
lines for ER, AR, VDR, PR, and Her2 expression. Two AR? and two
AR- prostate cancer cell lines, LNCaP, LAPC-4, PC-3, and DU-145,
respectively, were used as controls for AR expression. 30 lg extract
was loaded in each lane of a 4–12 % 20-well SDS-PAGE gel, which
was transferred onto a nitrocellulose membrane and probed with the
following antibodies: ERa (1:750, Santa Cruz sc-8002), progesterone
receptor (1:1000, Thermofisher Scientific MA1-410), HER2 (1:2000,
Abcam ab2428), androgen receptor (N-20) (1:1000, Abcam sc-816),
vitamin D receptor (1:1000, Thermofisher Scientific MA5-14617). b-
Actin is used as a loading control (1:5000, Sigma A2228). The results
of VDR and AR agonist treatment experiments in panels b and c are
plotted as percent viability of the cells in comparison to the vehicle
control. Error bars represent mean ± standard error of mean (SEM).
These experiments were repeated at least three times. The statistical
significance of the drug treatments was determined using two-tailed
Student’s T-test. *P\ 0.05, **P\ 0.01. Cal calcitriol, DHT
dihydrotestosterone. b VDR agonist calcitriol treatment on cancer
cell lines: breast cancer cell lines [black VDR(?) and hatched
VDR(- or low)] were plated in their respective media with complete
serum in triplicates. 24–48 h after plating, the cells were treated with
100 nM calcitriol for 6 days with media change containing fresh drug
every 3 days. At the end of the experiment, the cells were trypsinized,
stained with 0.1 % Trypan blue and viable cells were counted using
Cellometer. c AR agonist dihydrotestosterone (DHT) treatment of
cancer cell lines: all the cell lines were seeded at 30–40 % confluency
into 24-well plates in triplicates in phenol red-free media containing
charcoal stripped serum in order to exclude the interference from
androgenic hormones in serum [black AR(?) and hatched AR(- or
low expression)]. 48–72 h after plating, the cells were treated with
10 nM DHT for 8–10 days with media change every 3–4 days. At the
end of the experiment, the cells were trypsinized, stained with 0.1 %
Trypan blue and viable cells were counted using Cellometer. d The
HR0–3 phenotype designation of selected TNBC cell lines based on
AR/VDR expression and response to natural ligands
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Inhibition of TNBC cell lines
with dihydrotestosterone is AR dependent
While the notion of AR-targeted therapy for BC has been
around since the early 1970s [19–21], whether AR agonists
or AR antagonists should be used for this purpose has been
contentious. Many studies show that AR agonists inhibit
BC cell growth both in vivo and in vitro [22–30], and
others indicated that AR antagonists can also inhibit breast
tumor growth [31] and recently several clinical studies
were initiated with AR antagonists in BC patients [32, 33].
Hence, based on the prior literature, it was not entirely
clear whether AR agonists or antagonists should be used to
treat AR? TNBC. Thus, we started by testing the effects of
both AR agonists and antagonists in a panel of AR? and
AR- BC cell lines including all three subtypes (ER?,
HER2?, and TNBC). In addition, we used AR? and AR-
PCs as controls because PC cell lines have a well-estab-
lished and specific response to AR ligands.
We found that AR agonists dihydrotestosterone (DHT)
and R1881 stimulated proliferation of AR? PC cell lines as
expected. Importantly, there was no effect on AR- PC-3
cell line, which demonstrates that the effect of DHT and
R1881 on cell proliferation is AR dependent in PC cell
lines (Fig. 1c; Suppl. Fig. 1b).
Consistent with the opposing role of androgens in male
versus female, DHT or R1881 treatment resulted in a
decrease in cell proliferation and viability in AR? BC cell
lines (Fig. 1c; Suppl. Fig. 1b). The one exception was the
ER- HER2? BC cell lines in which AR agonists increase
cell proliferation (data not shown), which was shown to be
due to a cross-talk between HER2 and AR signaling
pathways that is only observed in ER- background [10, 34,
35]. There was no response to DHT or R1881 in AR- BT-
20, MDA-MB-468, and AR-low SUM-159PT cell lines
indicating that at the effect of DHT and R1881 on cell
proliferation is AR dependent in BC cell lines (Fig. 1c;
Suppl. Fig. 1a, b).
In summary, AR agonists DHT and R1881 decrease
proliferation of TNBC, ER?, and ER?/HER2? BC cell
lines and stimulate proliferation of ER-/HER2?/AR? cell
lines.
Inhibition of TNBC cell lines with AR antagonists is
not dependent on AR
Next, we tested the effect of AR antagonists on BC cell line
proliferation using three different drugs (flutamide, bica-
lutamide, and enzalutamide) on four AR? and three AR-/
low BC cell lines. In addition, two AR? and two AR- PC
cell lines were used as controls.
As expected, in PC cell lines, we observed a dose-de-
pendent decrease in cell proliferation and viability in AR?
cell lines at low concentrations compared to AR- cell lines
(Fig. 2a; Suppl. Fig. 2a). There was an approximately 5-fold
difference in the LD50 values between AR
? versus AR- PC
cell lines (Fig. 2b; Suppl. Fig. 2c), indicating that the
response to AR antagonists in PC cell lines is AR dependent.
Surprisingly, in BC cell lines, we did not observe a similar
difference in the LD50 values of AR antagonists in AR
?
versus AR- lines (Fig. 2d; Suppl. Fig. 2c). There was
decrease in cell proliferation in BC cell lines with AR
antagonists regardless of their AR protein expression
(Fig. 2c; Suppl. Fig. 2b). These results suggest that the
effect of AR antagonists in BC cell lines can be AR-inde-
pendent. Therefore, we concentrated on AR agonists as drug
of choice for further experiments in TNBC lines (Fig. 7a).
Treatment of TNBC with AR and VDR agonists
in combination with chemotherapy
We previously showed that nearly two-thirds of TNBC
have HR1-v (45 %) or HR2-av (18 %) phenotype, i.e.,
these tumors are negative for ER, PR, and HER2, but
positive for VDR (HR1-v) or both AR and VDR (HR2-av)
[1]. These TNBCs are currently treated with chemothera-
peutic agents such as Taxol or cisplatin.
We found that single agent VDR agonist (calcitriol) can
reduce proliferation of both HR1-v and HR2-av TNBC cell
lines (Fig. 1c), and combination of calcitriol with Taxol
resulted in an additive or synergistic decrease in cell pro-
liferation and viability in two different HR1-v TNBC lines
(Fig. 3a) using Bliss independence criterion approach [36–
38]. Additionally, similar results were observed when the
combination of calcitriol and Taxol was tested in two
TNBC lines, MFM-223, and CAL-148 (Suppl. Fig. 3).
In HR2-av TNBC cell lines, we found that combination
of AR and VDR agonists had an additive inhibitory effect
in two different HR2-av TNBC cell lines (Fig. 3b). Next,
we examined combining AR- and VDR-targeted therapy
with chemotherapy, and found that combination of AR
(DHT)- and VDR (calcitriol)-targeted therapy with Taxol
or cisplatin has an additive effect in reducing cell viability
(Fig. 3c, d).
It is worth pointing out that in order to demonstrate
additivity in these experiments, we used doses lower than
IC50 for each drug (Suppl. Fig. 4). Therefore, it is possible
to achieve a greater reduction in cell numbers and viability,
close to 100 % cell death, when these drugs are combined
between IC50 and IC90 dose range.
The mechanism of tumor cell inhibition by AR-
and VDR-targeted hormones
The VDR and AR agonists have been shown to have cell-
context dependent pleiotropic effects on cell cycle,
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apoptosis, autophagy, or differentiation depending on the
cell type and dose [13, 14, 25, 39–42]. Therefore, we
examined these potential mechanisms in HR2-av cell lines
MFM-223 and CAL-148.
There was an increase in G1 phase of the cell cycle in
MFM-223 with both DHT and calcitriol individually, and
their combination resulted in additive G0/G1 cell cycle
arrest (Fig. 4a). In contrast, we did not observe a change in
the cell cycle profile of CAL-148 with VDR or AR agonists
(Fig. 4b).
An increase in apoptosis was observed in CAL-148 with
combination of DHT and calcitriol evaluated by Annexin
V/PI co-staining (Fig. 4c) as well as PARP cleavage
(Fig. 4d). Importantly, the apoptotic effects of DHT and
calcitriol were minimal when they were used alone, con-
sistent with an additive effect. In contrast, there was no
change in apoptosis of MFM-223 cells with either hormone
alone or in combination (Fig. 4c, d). Since many
chemotherapeutic agents induce G2/M arrest followed by
apoptosis [43, 44], we examined whether combining DHT
and calcitriol with cisplatin in MFM-223 and CAL-148
would interfere with chemotherapy-induced G2/M arrest
and apoptosis. We also found that co-treatment with AR/
VDR agonists plus chemotherapy resulted in either no
change or additive increase in G2/M arrest and apoptosis in
MFM-223 and CAL-148 (Suppl. Fig. 5).
Fig. 2 Evaluation of androgen receptor antagonists response in BC
lines: a all the prostate cancer cell lines were seeded at 4000 cells/
well on black-colored clear bottomed 96-well plates [LNCaP and
LAPC-4, red lines AR(?) and PC-3 and DU-145, blue lines AR(- or
low)]. 24 h after plating, the cells were treated with AR antagonists
enzalutamide or bicalutamide for 4 days at concentrations ranging
from 0.1 to 100 lM and cell viability was measured by cell titer blue
reagent. The results were plotted as percent cell viability compared to
vehicle control versus the concentration of the drug. Error bars
represent mean ± SEM. b The IC50 values of enzalutamide and
bicalutamide in prostate cancer cell lines were calculated using Prism
software (version 6.05 GraphPad Software, Inc.) by non-linear
regression analysis. The lethal dose LD50 was calculated as described
in the ‘‘Materials and methods’’ section. Red bars AR(?) LNCaP and
LAPC-4. Blue bars AR(-/low) PC-3 and DU-145. (*) DU-145 cell
line did not reach 50 % inhibition, hence its LD50 value is[100 lM.
c All the breast cancer cell lines were seeded at 4000 cells/well on
black colored clear bottomed 96-well plates. Red lines AR(?) BC cell
lines CAL-148, ZR-75-1, BT-474, and MFM-223. Blue lines
AR(-/low) BC cell lines BT-20, MDA-MB-468, and SUM-159PT.
24 h after plating, the cells were treated with AR antagonists
enzalutamide or bicalutamide for 4 days at concentrations from 0.1 to
100 lM and cell number and viability was measured by cell titer blue
reagent. The results were plotted as percent cell viability compared to
vehicle control versus the concentration of the drug. Error bars
represent mean ± SEM. d The IC50 values of enzalutamide and
bicalutamide in breast cancer cell lines were calculated using Prism
software (version 6.05 GraphPad Software, Inc.) by non-linear
regression analysis. The lethal dose LD50 was calculated as described
in the ‘‘Materials and methods’’ section. Red bars AR(?), blue bars
AR(- or low)]
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Lastly, we found that autophagy did not change with co-
treatment of MFM-223 and CAL-148 cell lines with AR
and VDR (DHT and Cal), measured by FACS using Cyto-
ID fluorescent dye or by western blots for autophagy
marker LC3B (Suppl. Fig. 6).
Cumulatively, these results indicate that AR and VDR
stimulation can additively inhibit proliferation of BC cells
through cell cycle arrest or apoptosis depending on the cel-
lular context, suggesting a rationale for their combined use.
Furthermore, combining both hormones with chemotherapy
can additively increase apoptosis in cancer cell lines.
AR- and VDR-targeted hormones can inhibit cancer
stem cell phenotype
Both androgens and Vit-D are well-known regulators of
cellular differentiation [14, 40–42, 45–49]. Therefore, we
examined whether they also change the differentiation state,
CSC marker expression and tumorsphere formation effi-
ciency (TFE) of BC cell lines. We found that calcitriol sig-
nificantly inhibited TFE in both MFM-223 and CAL-148
cell lines and DHT inhibited TFE in CAL-148 (Fig. 5a;
Suppl. Fig. 7). No further decrease in TFE was observed
with co-treatment with both hormones at the doses we tested.
High aldehyde dehydrogenase (ALDH) activity is one of
the features of CSCs, which is measured by AldeFluor
assay [17, 50]. Consistent with the TFE results, we found
that treatment with AR or VDR agonists decreased
ALDH? cells additively resulting in 5–100-fold decrease in
the frequency of ALDH? cells with co-treatment of HR2-
av TNBC MFM-223 and CAL-148 cell lines (Fig. 5b;
Suppl. Fig. 8).
Next, we examined other CSC-associated markers
after treatment with AR or VDR agonists alone or in
Fig. 3 Evaluation of AR- and VDR-targeted therapy in combination
with chemotherapy in TNBC: the effect on cell viability was
measured after 8 days of treatment with various drugs listed in a–
d by counting viable cells after 0.1 % Trypan blue staining using
Cellometer in all experiments. Whether the combination of drugs
resulted in additive, synergistic, or antagonistic interactions was
determined by Bliss independent criterion approach, explained in
detail in the supplemental methods. Y-axis represents percentage
viability of the cells after treatment compared to vehicle control.
Error bars represent mean ± SEM. Cal calcitriol, DHT dihy-
drotestosterone, Cis cisplatin, Tax paclitaxel.  represents additive
effect on the combination of drugs and § represents additive or
synergistic effect. a VDR-targeted therapy in combination with
paclitaxel (Taxol) in TNBC HR1-v cell lines. Two VDR(?) TNBC
lines BT-20 and SUM-159PT were treated with vehicle (gray bar),
calcitriol (black bars 10 nM) or Taxol (white bar BT-20: 1 nM,
SUM-159PT: 0.5 nM) or a combination of calcitriol and Taxol
(hatched bar) for 6 days with media change with fresh drug every
3 days. b Combination of AR- and VDR-targeted therapy in TNBC
HR2-av cell lines. MFM-223 and CAL-148 cell lines were treated
with DHT (black bar 10 nM), calcitriol (white bar MFM-223: 25 nM
and CAL-148: 10 nM), or combination of DHT and calcitriol
(hatched bars). c Combination of AR- and VDR-targeted therapy
with paclitaxel in TNBC HR2-av cell lines. MFM-223 and CAL-148
cell lines were treated with DHT (black bar 10 nM), Taxol (white bar
0.5 nM), calcitriol (single hatched bar MFM-223: 25 nM and CAL-
148: 10 nM), or combination of DHT ? calcitriol ? Taxol (double
hatched black bar). d Combination of AR- and VDR-targeted therapy
with cisplatin in TNBC HR2-av cell lines. MFM-223 and CAL-148
cell lines were treated with DHT (black bar 10 nM), cisplatin (white
bar 10 nM), calcitriol (single hatched bar MFM-223: 25 nM and
CAL-148: 10 nM), or combination of DHT ? calcitriol ? cisplatin
(double hatched black bar)
82 Breast Cancer Res Treat (2016) 157:77–90
123
combination; we found that CD49f, Musashi, CD133,
and CD326 are down-regulated with combination treat-
ment (Fig. 5c). In addition, we observed an increase in
differentiation markers Claudin-4 and cytokeratin 18 and
down-regulation of cytokeratin 5 (MFM-223) as well as
reciprocal down-regulation of vimentin and up-regula-
tion of cytokeratin 18 (CAL-148) consistent with more
differentiated epithelial phenotype (Fig. 5d; Suppl.
Fig. 9).
Lastly, we used a PCR-based CSC pathway array that
includes 84 common CSC-associated genes and found a
2–5-fold decrease in the mRNA expression of CD44,
SOX2, MME (CD10), ALDH1A1, and PPAR-gamma with
AR and VDR hormone co-treatment compared to control
(Fig. 5e).
Cumulatively, these results indicate that in addition to
increasing apoptosis and cell cycle arrest, AR and VDR
agonists also inhibit CSC phenotype and induce differen-
tiation in HR2-av TNBC cell lines.
Synthetic AR and VDR ligands can be used to treat
HR2-av TNBC cell lines
One concern with using natural AR agonists in the clinic is
the potential virilizing side effects and aromatization to
estrogens, which can be overcome by a new class of drugs,
known as non-steroidal selective AR modulators (SARMs).
We selected to test SARM compound enobosarm (GTx-
024), since it is currently being tested in clinical trials [51].
We found that similar to AR agonists DHT and R1881,
GTx-024 increased proliferation of AR? PC cell line
LNCaP, and inhibited proliferation of AR? BC cell lines.
This effect was specific to AR because GTx-024 had no
effect on AR- PC and BC cell lines (Fig. 6a).
The natural Vit-D ligands can cause hypercalcemia in
patients, which prevents achieving clinically effective anti-
tumor activity. However, over 1500 Vit-D analogs have
been synthesized which may potentially have low calcemic
effect [52–54]. We selected seocalcitol (EB1089), since its
Fig. 4 Analysis of cell cycle and apoptosis after AR and/or VDR
therapy: a, b the effect of DHT or calcitriol treatment on cell cycle
was analyzed in TNBC cell lines MFM-223 (a) and CAL-148 (b) with
DHT (10 nM, black bars) or calcitriol (10 or 25 nM, white bars) or
DHT ? calcitriol (hatched bars) after 4 days. After BrdU incorpo-
ration, cells were fixed and stained with 2 lg anti-BrdU FITC
antibody and 50 lg/ml propidium iodide solution and evaluated by
flow cytometric analysis. Y-axis represents percentage population of
cells in a given phase (G1, S or G2/M) of cell cycle. Error bars
represent mean ± SEM. Statistical analysis was carried out compared
to the control group. *P\ 0.05, **P\ 0.01. c The effect of DHT or
calcitriol treatment on apoptosis was analyzed in TNBC cell lines
MFM-223 and CAL-148 that were treated with DHT (10 nM, black
bars) and calcitriol (10 or 25 nM, white bars) alone or in combination
(hatched bars) for 4 days. A positive control with 10 lM etoposide
treatment was included in the experiments (dotted bar). All the cells
(attached and floating) were collected, double stained with Annexin V
and propidium iodide to identify apoptotic cells. Y-axis represents the
combined early and late apoptotic cell population. The error bars
represent mean ± SEM. Statistical analysis was carried out compared
to the control group. *P\ 0.05, **P\ 0.01. d PARP cleavage as a
measure of apoptosis was measured with Western blots in HR2-av
TNBC cell lines treated with DHT or calcitriol. MFM-223 and CAL-
148 treated as described in panel c and were harvested with RIPA
buffer. 30 lg Protein was loaded in each well 7.5 % SDS-PAGE gel;
after gel transfer on to nitrocellulose membrane, they were probed
with anti-PARP antibody (1:1000, Cell Signaling 9542). b-Tubulin
was used as a loading control
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affinity to VDR is similar to natural ligand calcitriol, yet it
has a 50–200-fold higher anti-proliferative activity and
reduced hypercalcemic effect [55, 56]. We found that
treatment of HR1-v and HR2-av cell lines with EB1089
resulted in a dose-dependent decrease in cell viability.
Moreover, as reported before, EB1089 treatment was more
potent than calcitriol at low doses (Fig. 6b; Suppl.
Fig. 10a).
Next we examined combining synthetic VDR agonist
EB1089 with chemotherapy in HR1-v BC cell lines, and
found that there is an additive decrease in cell viability
when EB1089 is combined with cisplatin or Taxol (Fig. 6c;
Suppl. Fig. 10b). Furthermore, combining GTx-024 and
EB1089 with or without Taxol produced additive inhibition
of cell viability of the TNBC cell lines (Fig. 6d, e; Suppl.
Fig. 10c, d). Cumulatively, these results suggest that AR-
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and VDR-targeted hormone therapy should be considered
in the clinic using synthetic AR and VDR ligands with
lower virilizing and calcemic side effects.
Discussion
In brief, our study demonstrates that two different hor-
mones that activate AR and VDR can be used alone, in
combination with each other as well as with chemotherapy
to inhibit proliferation of TNBC cell lines by increased
apoptosis and G1/S arrest. In addition, these hormones
inhibit TNBC CSC phenotype and induce differentiation.
These observations raise the possibility of targeting
approximately two-thirds of the TNBCs [1] with AR and/or
VDR HR-targeted therapies.
Vitamin D receptor: its role in breast cancer
treatment
VDR is expressed in around 90 % of the breast tumors
[57]. Of the six natural Vit-D compounds, calcitriol is the
most active and stable form of Vit-D [52]. Several clinical
trials have been conducted with calcitriol as a single agent
in breast tumors, with the conclusion that the therapeutic
dose required to induce anti-tumor activity is difficult to
achieve due to hypercalcemia, renal stones [52, 58, 59],
and vascular calcification [60]. Therefore, VDR agonists
with low calcemic effects are needed to translate our
findings to the clinic. Only a few of the more than 1500
Vit-D analogs have been tested in vivo so far [52–54].
Seocalcitol (EB1089) which we used in our study was
tested in a Phase-I clinical trial and was found to be well
tolerated and had some activity in BC patients [61].
The role of androgen agonists in breast cancer
treatment
In early 1970s, post-menopausal women with breast cancer
were treated with testosterone with favorable responses [62–
65]. However, conversion of testosterone into estrogens in
tissues [66, 67], virilizing side effects, and development of
effective anti-ER therapies as an alternative have slowed
further development of AR-targeted therapy for BC [68]. An
additional challenge was the seemingly discrepant response
to AR agonists in different cell lines [22, 25–27, 69, 70].
However, a recent review of ER? BC cell lines suggest that
while experimental variations in cell density, serum, drugs,
and cell counting methods contributed to conflicting results,
in the studies that reported a response to AR agonists
(n = 33), the majority (78 %) showed that AR activation
results in inhibition of cell proliferation in ER? BC lines
[68]. In ER-/HER2? BC, it was shown that the growth
inhibitory effect of AR agonists is switched into growth
stimulation by the cross-talk between HER2 and AR [10, 34,
35]. But, this switch only occurs in ER- cells, i.e., AR
agonists stimulate proliferation in ER-HER2? cell lines, but
inhibit proliferation in ER? HER2? cell lines. In addition to
these preclinical data, it was found that high AR expression
correlates with low grade and better outcome in BC [71] and
we previously reported that AR expression is mutually
exclusive with proliferation in human BC sections [1]. We
also found that SARMs such as GTx-024 are effective in
inhibiting proliferation of BC cell lines and showed clinical
activity in a Phase II trial with few virilizing side effects [51,
72–74]. Cumulatively these observations indicate that AR
bFig. 5 Effect of AR and/or VDR therapy on cancer stem cell and
differentiation phenotype: a the effect of DHT and calcitriol on
tumorsphere formation in TNBC HR2-av cell lines MFM-223 and
CAL-148. The cells were trypsinized and single cell suspensions were
plated into six-well low adhesion plates in 4-ml sphere media (seeding:
MFM-223 10,000 and CAL-148 6000) containing DHT (10 nM, black
bars) or calcitriol (MFM-223 25 nM and CAL-148 10 nM,white bars),
or DHT ? calcitriol (hatched bars). After 2 weeks during which
spheres are formed from single cells, the plates were stained with iodo-
nitrotetrazolium chloride overnight and the spheres were counted using
GelCount. Y-axis represents the TFE, tumorsphere formation efficiency
(number of spheres formed per the number of cells seeded in a well)
represented as fold change in comparison to control group (no
treatment, vehicle only). The statistical significance of the drug
treatments was determined using two-tailed Student’s T-test. Error
bars represent mean ± SEM. *P\ 0.05, **P\ 0.01. b AldeFluor
assay on HR2-av cell lines MFM-223 and CAL-148 after AR and VDR
treatment. The cells were treated as described in panel a for 8 days with
media change containing fresh drug every 3 days and ALDH?
population was examined by AldeFluor assay kit using FACS profiles
representing ALDH? population before (top) and after (bottom) co-
treatment. The graph shows ALDH? cells plotted as percentage in each
treatment group.Gray bar vehicle treatment, black barDHT,white bar
Cal, hatched DHT and Cal combination. Error bars represent
mean ± SEM. The statistical significance of the drug treatments was
determined using two-tailed Student’s T-test. *P\ 0.05, **P\ 0.01.
c, d Western blot analysis of differentiation and cancer stem cell
markers in HR2-av cell lines MFM-223 and CAL-148 after DHT and
calcitriol treatment. The cells were treated with DHT (10 nM) and/or
calcitriol (MFM-223: 25 nM and CAL-148: 10 nM) for 8 days with
media including drug every 3 days. The cell lysates with 30 lg protein
were loaded in each lane of a 4–15 % SDS-PAGE gel and after transfer
to nitrocellulosemembrane, it was probedwith the following antibodies
at appropriate dilutions: E-cadherin (BD Biosciences 61081), vimentin
(Sigma 5255), cytokeratin 5 (Abcam ab75869), cytokeratin 18 (Ther-
mofisher Scientific MS-142-P), Claudin-4 (Invitrogen 32-9400),
ALDH1A1 (Cell Signalling mAb12035), CD326 (Abcam ab32392),
CD49f (ABD Serotec MCA1457), CD133 (Sigma C9493), CD24
(Santa Cruz SC-53660), CD166 (Abcam ab49496), Nanog (Abcam
ab109250), and Musashi (Abcam ab52865). b-Actin or b-tubulin were
used as loading controls. e mRNA expression of stem cell markers.
MFM-223 cells were treated with 10 nM DHT and/or 25 nM calcitriol
for 96 h. ThemRNAwas quantified using a PCR-based array (Qiagen).
The expression level of each gene was determined by comparing the
treatment to vehicle control, and geneswithmore than 2-fold change are
presented here in a Heatmap generated using conditional formatting in
Microsoft Excel. Scale bar red represents high expression, green
represents low expression
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agonists can inhibit proliferation of AR? BC, except in ER-
HER2? tumors (Fig. 7).
The role of androgen antagonists in breast cancer
treatment
In our study, AR antagonists inhibited proliferation of all
BC cell lines regardless of their high, low or negative AR
expression status. This is very different than the observa-
tions in PC in which there was a [5-fold difference
between in the LD50 of AR antagonists in AR
? versus AR-
PC cell lines. Importantly, AR-independent inhibition of
TNBC cell line proliferation was observed with all three
antagonists indicating that this is not an isolated finding.
Furthermore, the response of the same TNBC cell lines to
the AR agonists DHT and R1881 was AR-specific, which
indicates that these TNBC cell lines have a functional AR
receptor. At the same time, the response of PC cell lines to
AR antagonists was AR dependent ruling out method-
ological errors. These results indicate that the anti-prolif-
erative effect of AR antagonists in BC cell lines may
possibly be due to an off-target effect. Thus, while these
drugs have some activity in the clinic, whether this is
through AR or some other target remains to be determined.
It is worth pointing out that it is already known that some
AR antagonists can have non-AR activities; for example,
enzalutamide inhibits GABA-A receptors [75], bicalu-
tamide inhibits CYP27A1 [76], and both flutamide and
bicalutamide bind to PR [77]. Hence it is possible that
these drugs may have activity in cells that are ostensibly
negative for AR activity through other genes that are yet to
be discovered. Therefore, genetic background of these
individual cell lines may play a role in the AR antagonist
response in BC cell lines. However, one might have
Fig. 6 Selective androgen receptor modulators and VDR analogs
alone or in combination results in anti-proliferative effects: for all the
panels a–e, the Y-axis represents percentage viability of the cells after
drug treatment compared to vehicle control. Error bars represent
mean ± SEM. The statistical significance was validated by two-tailed
Students T-test compared to vehicle control. *P\ 0.05, **P\ 0.01.
The combination of drugs resulted in additive, synergistic or
antagonistic was determined by Bliss independent criterion approach,
explained in detail in the supplemental methods.  Represents
additive effect on the combination of drugs and § represents additive
or synergistic effect. a Selective androgen receptor modulator
(SARM) treatment in breast and prostate cancer cell lines. All the
cell lines [black AR(?) and hatched AR(- or low)] were treated with
SARM compound GTx-024 at 100 nM concentration for 8–10 days
with media change every 3 days. The cells were then trypsinized,
stained with 0.1 % Trypan blue and viable cells were counted using
Cellometer. b Comparison of VDR agonist analog EB1089 and
calcitriol treatment in TNBC cell lines. Selected TNBC cell lines that
express VDR (BT-20, SUM-159PT, MFM-223 and CAL-148) were
treated with either 5 nM calcitriol (gray bar) or 5 nM EB1089 (black
bar) for 6 days with media change every 3 days. The viable cells
were counted after staining with 0.1 % Trypan blue. c Combination of
VDR agonist analog EB1089 with chemotherapy drug paclitaxel in
TNBC HR1-v cells lines. BT-20 and SUM-159PT cell lines were
treated with EB1089 and/or paclitaxel for 6 days and viable cells
were counted using Cellometer. EB1089 (black bars BT-20 1 nM,
SUM-159PT 2.5 nM), Taxol (white bars BT-20 1 nM, SUM-159PT
0.5 nM), combination of EB1089 ? Taxol (hatched bars). d Combi-
nation of SARM compound GTx-024 with VDR analog EB1089 in
HR2-av TNBC cell line MFM-223. Gray bar vehicle, black bar GTx-
024 (100 nM), white bar EB1089 (0.5 nM), hatched bar combination
of GTx-024 and EB1089. e Triple combination of SARM GTx-024,
VDR analog EB1089 and Taxol in HR2-av TNBC cell line MFM-
223. Gray bar vehicle, black bar GTx-024 (100 nM), white bar Taxol
(0.75 nM), single hatched bar EB1089 (0.5 nM), double hatched
black bar combination of all the three drugs
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expected the genetic background could affect agonist
response equally, which was not the case. The seemingly
off-target AR-antagonist effect appears to emerge only in
breast cells and not in prostate cells, which may be due to
tissue-specific regulation of signaling pathways. For
example, at the gene expression level, it was found that AR
binds to the PTEN promoter as a repressor, inhibiting its
transcription in PC cells. In contrast, AR stimulates PTEN
gene expression as an activator in BC cells [78]. Therefore,
while surprising, the tissue-specific drug response may not
be completely unexpected. Many drugs have unexpected
activities due to binding to unknown targets or unknown
interactions between the known drug target and other
biochemical pathways [79].
Role of hormones in inhibiting CSC population
There is growing evidence that BCs consist of a hetero-
geneous population of different subtypes of cells including
non-CSCs and CSCs that possess the ability of self-renewal
[80, 81] and thought to be associated with resistance to the
standard therapies and metastasis [82, 83]. Hence, targeting
CSCs may be important for complete tumor remission.
We found that hormonal co-stimulation of AR and VDR
simultaneously leads to reduction of CSC population,
evidenced by a decrease in TFE, decrease in ALDH
activity and down-regulation of markers associated with
the CSC phenotype. High expression of CD49f regulates
pluripotency factors such as OCT4 and SOX2 [84] and
Musashi regulates Notch which is one of the key pathways
that regulate self-renewal potency of the cells [85, 86].
Therefore, inactivation of CD49f, SOX2, and Notch sig-
naling may provide a mechanism through which AR and
VDR treatment can decrease CSC population.
In summary, we show that co-targeting AR and VDR
with agonist hormones can be an effective strategy to target
CSCs. Our results also suggest that the selection of AR
agonists in the treatment of BC will depend on ER and
HER2 status, and combination of AR and VDR agonists
can be additive with chemotherapy.
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